Patents by Inventor Julien Schmidt

Julien Schmidt has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 12195556
    Abstract: Some aspect of this disclosure provide reversible MHC protein multimers, and methods of using such multimers in the detection and/or isolation of specific T-cells or T-cell populations. Because reversible MHC multimers can efficiently be dissociated, the time of MHC binding to T-cell receptors, and, thus, T-cell receptor-mediated T-cell activation can be minimized. The use of reversible MHC multimers as provided herein, accordingly, allows for the detection and isolation of bona fide antigen-specific CD8+ T cells without inducing activation dependent cell death, including rare, therapeutically valuable T-cells expressing T-cell receptors binding tumor antigens with high affinity. Methods for the production and use of reversible multimers are also provided.
    Type: Grant
    Filed: June 14, 2018
    Date of Patent: January 14, 2025
    Assignee: Ludwig Institute for Cancer Research Ltd.
    Inventors: Immanuel F. Luescher, Julien Schmidt, Philippe Guillaume, Danijel Dojcinovic
  • Publication number: 20180346606
    Abstract: Some aspects of this invention are based on the recognition that reversible protein multimers in which monomeric proteins are conjugated to a carrier molecule via chelation complex bonds are stable under physiological conditions and can be dissociated in a controlled manner under physiological, nontoxic conditions. Accordingly, such protein multimers are useful for a variety of in vitro, ex vivo, and in vivo application for research, diagnostics, and therapy. Some aspect of this invention provide reversible MHC protein multimers, and methods of using such multimers in the detection and/or isolation of specific T-cells or T-cell populations. Because reversible MHC multimers can efficiently be dissociated, the time of MHC binding to T-cell receptors, and, thus, T-cell receptor-mediated T-cell activation can be minimized.
    Type: Application
    Filed: June 14, 2018
    Publication date: December 6, 2018
    Applicant: Ludwig Institute for Cancer Research Ltd.
    Inventors: Immanuel F. Luescher, Julien Schmidt, Philippe Guillaume, Danijel Dojcinovic
  • Patent number: 10023657
    Abstract: Some aspects of this invention are based on the recognition that reversible protein multimers in which monomeric proteins are conjugated to a carrier molecule via chelation complex bonds are stable under physiological conditions and can be dissociated in a controlled manner under physiological, nontoxic conditions. Accordingly, such protein multimers are useful for a variety of in vitro, ex vivo, and in vivo application for research, diagnostics, and therapy. Some aspect of this invention provide reversible MHC protein multimers, and methods of using such multimers in the detection and/or isolation of specific T-cells or T-cell populations. Because reversible MHC multimers can efficiently be dissociated, the time of MHC binding to T-cell receptors, and, thus, T-cell receptor-mediated T-cell activation can be minimized.
    Type: Grant
    Filed: September 30, 2011
    Date of Patent: July 17, 2018
    Assignee: Ludwig Institute for Cancer Research Ltd.
    Inventors: Immanuel F. Luescher, Julien Schmidt, Philippe Guillaume, Danijel Dojcinovic
  • Publication number: 20130289253
    Abstract: Some aspects of this invention are based on the recognition that reversible protein multimers in which monomeric proteins are conjugated to a carrier molecule via chelation complex bonds are stable under physiological conditions and can be dissociated in a controlled manner under physiological, nontoxic conditions. Accordingly, such protein multimers are useful for a variety of in vitro, ex vivo, and in vivo application for research, diagnostics, and therapy. Some aspect of this invention provide reversible MHC protein multimers, and methods of using such multimers in the detection and/or isolation of specific T-cells or T-cell populations. Because reversible MHC multimers can efficiently be dissociated, the time of MHC binding to T-cell receptors, and, thus, T-cell receptor-mediated T-cell activation can be minimized.
    Type: Application
    Filed: September 30, 2011
    Publication date: October 31, 2013
    Applicant: Ludwig Institute for Cancer Research Ltd.
    Inventors: Immanuel F. Luescher, Julien Schmidt, Philippe Guillaume, Danijel Dojcinovic